A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

NCT05861947 ↗

Phase 1 Terminated 21 enrolled Aurigene Discovery Technologies Limited

NaSequentialOpen-labelTreatment

Summary

A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients with Select Relapsed Advanced Malignancies (JIVAN).

Timeline

Start: 2023-08-26
Primary completion: 2026-02-10
Completion: 2026-02-10

Outcome

Outcome not reported

Stopped (Enrollment): “Patient recruitment problems”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AUR106	Unknown	25 mg	Oral
Subject	AUR106	Unknown	50 mg	Oral
Subject	AUR106	Unknown	100 mg	Oral

A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies

Summary

Timeline

Outcome

Drugs

Indications